

# Enhancing Outcomes in Type 2 Diabetes and Chronic Kidney Disease with Novel Treatments

SGLT2i in preserving renal health and preventing cardiovascular events



Sabina Yasmin, Advanced Clinical Pharmacist  
Well Street Common PCN

## Aim


- Identify adults living with Type 2 Diabetes (T2DM) and Chronic Kidney Disease (CKD) 3-5 and prioritise patients from Black, Asian and Minority Ethnic (BAME) backgrounds, *then*
- Initiate SGLT2i medication in 75% of this group by project end

## Method

- Extract data using EMIS clinical searches to identify priority patients
- Verify CKD coding and update blood/urine test results as needed
- Offer SGLT2i therapy to eligible patients based on current evidence

## Summary of Results

- 24 patients identified – 4 excluded as contraindicated
- 12 patients needed up to date renal profiles
- 75% of this cohort (15 patients) were started on SGLT2i
- 25% (5 patients) declined treatment



## Sustaining the Change

- Share data of improved outcomes to clinical team to motivate further prescribing
- Provide training to allied health professionals so clinicians are confident in prescribing SGLT2i
- Innovate by using EMIS pop ups or template updates to flag eligible patients at care encounters
- Use local dashboards to monitor progress

## Learnings

- Ethnicity:** Information may be missing or inaccurate. Ask confidently and explain its importance: understanding health inequalities helps identify and support those at higher risk of cardiovascular events.
- Treatment decliners:** All five patients who declined treatment were male; further exploration is warranted given the risk of Fournier’s gangrene and increased susceptibility to UTIs.
- SGLT2i use:** Considered the third step in CKD management; some patients were not on first- or second-line therapies despite being suitable.

### Patient feedback

*“The pharmacist had taken the time to review my medications carefully, and it showed in the confidence and clarity of her words.”*

### Patient feedback

*“It felt good to speak with someone so knowledgeable, who truly cared about my wellbeing. I felt empowered, knowing that I was in good hands.”*

## Contact Details



@UCLPartners

@UCLPartners

@UCLPartners

uclpartners.com



UCLPartners CVD Academy is being part funded by sponsorship from Boehringer Ingelheim, Novo Nordisk & Daiichi Sankyo. Boehringer Ingelheim, Novo Nordisk & Daiichi Sankyo have had no input or influence into the arrangements, creation of the content or selection of delegate or faculty members associated with this programme.